Grant RDF
pages:- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10
- 11
- 12
- 13
- 14
- 15
- 16
- 17
- 18
- 19
- 20
- 21
- 22
- 23
- 24
- 25
- 26
- 27
- 28
- 29
- 30
- 31
- 32
- 33
- 34
- 35
- 36
- 37
- 38
- 39
- 40
- more...
- A Phase II Clinical Trial of the Cdk 4/6 Inhibitor, Pd 0332991 in Previously-Treated, Advanced Nsclc Patients With Wildt
- A Phase II Double-Blinded, Randomized, Placebo-Controlled Study of Docetaxel in Combination With 1-Methyl-D-Tryptophan
- A Phase II Evaluation of the Safety and Efficacy of the Trivascular Enovis Aaa S
- A Phase II Multicenter Open Label Single Arm Study of Sar302503 in Subjects Previously Treated With Ruxolitinib...
- A Phase II Multicenter Randomized Double-Blind Placebo- Controlled Study to Evaluate the Safety and Efficacy......
- A Phase II Multicenter, Randomized, Double-Blind, Two-Stage Clinical Trial to Evaluate the Efficacy and Safety of MK-0594 in Patients with Alcohol Dependence
- A Phase II Open Label Controlled Randomized Study of the Cdx-1307 Vaccine Regimen As Neoadjuvant and Adjuvant Therapy in
- A Phase II Open-Label Extension Study to Evaluate the Long Term Safety of Rhumab Beta7 in Patients With Moderate To....
- A Phase II Randomized Controlled Trial of Genomically Directed Therapy After Preoperative Chemotherapy....
- A Phase II Randomized Double Blind Placebo Controlled Dose Response Study of the Efficacy Safety and Tolerability of ...
- A Phase II Randomized Multicenter Placebo-Controlled Blinded Study of Sorafenib Adjuvant Therapy in High Risk Orthotopic Liver Transplant (OLT) Recipients with Hepatocellular Carcinoma (HCC)
- A Phase II Randomized Study Comparing Two Doses of Carfilzomib (Nsc0756640) With Dexamethasone for Multiple
- A Phase II Randomized, Double-Blind, Placebo Controlled Studstudy to Evaluate the Safety and Efficacy of a Single Dose..
- A Phase II Randomized, Double-Blind, Placebo-Controlled Study of Sorafenib or Placebo in Combination With Transarterial
- A Phase II Single Center Study in Healthy Subjects Undergoing Orthodontic Peocedures
- A Phase II Study of Allogeneic Transplant for Older Patients With Aml in First Morphologic Complete Remission Using.....
- A Phase II Study of Avn944 in Combination With Gemcitabine for the Treatment of Pancreatic Cancer
- A Phase II Study of Rindopepimut/Gm-Csf in Patients With Relapsed Egfrviii-Positive Glioblastoma
- A Phase II Study of Telaprevir (Vx-950) in Combination With Peginterferon Alfa 2a (Pegasys) and Ribavirin (Copegus).....
- A Phase II Tiral of Perifosine in Patients With Chemo- Insensitive Sarcomas
- A Phase II Trial of External Beam Radiation Therapy and Cetuximab Followed By Irinotecan and Cetuximab for Children.....
- A Phase II Trial of Non-Myeloablative Allogenic Hematoppietic Stem Cell Transplantation.......
- A Phase Ii Trila of Interleukin-2 Plus Thalidomide with Locally Advanced Metastic Melanoma and Metastic Renal Cell...
- A Phase Ii, Double-Blind, Placebo-Controlled, Randomized, Parallel-Group, Multicenter, Study to Evaluate the Efficacy...
- A Phase Ii, Multctr, Opn-Label Study to Evaluate Ovarian Activity with Three Doses of Trimegestone in Combination W
- A Phase Ii, Multi-Center, Double-Blind, Flexible Dose Study of Zp120 Administered As I.V. Infusion As Add-On Therapy....
- A Phase Ii, Multicenter, Randomized, Controlled, Open-Label Study of the Safety and Efficacy of Nutropin Aq............
- A Phase II, Randomized, Double-Blinded, Multi-Center, Dose Finding Study Evaluating the Efficacy and Safety of the HCV Polymerase Inhibitor Prodrug (RO4588161) When Given in Combination with Pegasys and Copegus versus the Currently Approved Combination of Pegasys and Copegus in Treatment-Naïve Patients with Chronic Hepatitis C Genotype a Virus Infection
- A Phase II, Randomized, Double-Blinded, Multicenter, Dose Finding Study Evaluating the Efficacy and Safety of the HCV Po
- A Phase II, Randomized, Multicenter, Double-Blinded Study Evaluating the Safety and Tolerability of the HCV Polymerase Inhibitor Prodrug (RO4588161) When Given in Combination with Pegasys With or Without Copegus Versus the Currently Approved Combination of Pegasys and Copegus in Treatment-Naïve Patients with Chronic Hepatitis C Genotype 1 Virus Infection